Cost effectiveness of extending human papillomavirus vaccine administration until age 45
1. The FDA approved the expansion of the human papillomavirus (HPV) vaccination from ages 9 to 26 in women and 21 in men to...
Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally...
1. Compared to standard photon therapy, proton chemoradiotherapy resulted in significantly reduced reduction in adverse events without changing disease-free or overall survival rates.Evidence Rating...
Clinician vs Patient Reporting of Baseline and Post-Baseline Symptoms for Adverse Event Assessment in...
1. Across 26 cancer clinical trials, researchers detected fewer baseline symptoms than those reported by patients, suggesting that adjustments to baseline determinations in clinical...
Niraparib increases progression-free survival in patients with ovarian cancer
1. Niraparib, a PARP (polyadenosine diphosphate ADP-ribose polymerase) inhibitor, has been associated with an increase in progression-free survival among patients with recurrent ovarian cancer.2....
Olaparib plus bevacizumab for ovarian cancer maintenance therapy
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy.2. The progression-free survival benefit...
Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled...
1. Certain dietary supplements, including vitamin B12, iron and omega-3 fatty acids, may negatively impact disease-free survival and overall survival in breast cancer patients...
Osimertinib associated with longer overall survival versus comparator EGFR-TKIs
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in a longer median overall...
Immune Status and Associated Mortality After Cancer Treatment Among Individuals With HIV in the...
1. Chemotherapy and/or radiotherapy may provoke significant declines in CD4 counts in HIV patients as compared to other treatments, which in turn are associated...
Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for...
1. Laparoscopic-assisted distal gastrectomy is non-inferior to open distal gastrectomy for clinical stage IA and IB gastric cancer in terms of relapse-free survival at...
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
1. Polatuzumab vedotin in combination with bendamustine and rituximab yielded higher complete response rates than bendamustine and rituximab alone.Evidence Rating Level: 1 (Excellent)Diffuse large...
